Purpose: To measure microdistibution and age of 210Pb in Canadian caribou bone, and assess the accuracy of ICRP biokinetic and dosimetric models for 210Pb-supported 210Po at bone surfaces.
Materials And Methods: The previously described use of alpha spectroscopy to study 210Pb microdistribution at bone surfaces was expanded in a study of femora from 23 caribou. A new technique for measuring the age in vivo of Pb in bone, on the basis of the ratio of 210Po/210Pb activity, was carried out on eight caribou femora.
Results: The measured thickness p of the layer containing elevated concentration of 210Pb at femoral endosteal surfaces was 0.79 +/- 0.52 microm (SD). This thickness increased linearly with age in caribou aged 2-11 years. The surface/volume concentration ratio of 210Pb (As/Av) varied from 1 to 18, geometric mean 3.8. No trend in As/Av with caribou age was observed. In the upper 1 microm/210Pb was 17 +/- 22 days old, and at depths of 1-22 microm the age was 146 +/- 17 days. Thus Pb at the bone surface was about nine times younger than in underlying bone.
Conclusions: Modifications to the ICRP 67 biokinetic model for Pb are proposed. The alpha dose to tissue above endosteal surfaces is reduced three times due to the low ingrowth ratio of 210Po.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/095530098142716 | DOI Listing |
Diagnostics (Basel)
January 2025
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone involvement, a myeloma-defining event, represents a major source of morbidity for patients. Key goals for the management of myeloma precursor conditions include (1) identifying patients at the highest risk for progression to MM with bone involvement and (2) differentiating precursor states from active myeloma requiring treatment.
View Article and Find Full Text PDFBone Marrow Transplant
January 2025
Vanderbilt University Medical Center, Nashville, TN, USA.
Blood Cancer J
December 2024
Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM. These disparities are multifaceted and intersect with various factors, including demographics, geography, socioeconomic status, genetics, and access to healthcare.
View Article and Find Full Text PDFHematology Am Soc Hematol Educ Program
December 2024
Department of Lymphoma/Myeloma and Department of Stem Cell Transplantation/Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Hodgkin lymphoma (HL) is a rare hematologic malignancy with a bimodal distribution of incidence, with most patients diagnosed between the ages of 15 and 30 years and another peak in patients older than 55 years. It is estimated that in 2023, almost 9000 people were diagnosed with HL in the United States. Most patients will be cured using conventional chemotherapy and radiotherapy.
View Article and Find Full Text PDFSci Rep
November 2024
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Patients who develop chimeric antigen receptor (CAR) T-cell-related immune effector cell-associated neurotoxicity syndrome (ICANS) frequently undergo evaluation with electroencephalography (EEG). We hypothesize that EEG features and Synek scale score, a measure of degree of EEG abnormality, are associated with ICANS severity. Here, we performed a retrospective review of 125 adult patients at Memorial Sloan Kettering Cancer Center (MSKCC) who received CAR-T cell therapy from 2010 to 2019, including 53 patients with B-acute lymphoblastic leukemia treated with 1928z CAR T cells (NCT01044069) and 72 patients with large B-cell lymphoma (LBCL) treated with the commercial CAR T products axicabtagene ciloleucel or tisagenlecleucel.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!